...
首页> 外文期刊>Epilepsia: Journal of the International League against Epilepsy >Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus.
【24h】

Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in status epilepticus.

机译:癫痫持续状态静脉注射左乙拉西坦的安全性和药代动力学。

获取原文
获取原文并翻译 | 示例

摘要

PURPOSE: To evaluate the feasibility and safety of intravenous (iv) levetiracetam (LEV) added to the standard therapeutic regimen in adults with status epilepticus (SE), and as secondary objective to assess a population pharmacokinetic (PK) model for ivLEV in patients with SE. METHODS: In 12 adults presenting with SE, 2,500 mg ivLEV was added as soon as possible to standardized protocol, consisting of iv clonazepam and/or rectal diazepam, as needed followed by phenytoin or valproic acid. ivLEV was administered over approximately 5 min, in general after administration of clonazepam, regardless the need for further treatment. During 24-h follow-up, patients were observed for any clinically relevant side-effects. Blood samples for PK analysis were available in 10 patients. A population PK model was developed by iterative two-stage Bayesian analysis and compared to PK data of healthy volunteers. RESULTS: Eleven patients with a median age of 60 years were included in the per protocol analysis. Five were diagnosed as generalized-convulsive SE, five as partial-convulsive SE, and one as a nonconvulsive SE. The median time from hospital admission to ivLEV was 36 min. No serious side effects could be related directly to the administration of ivLEV. During PK analysis, four patients showed a clear distribution phase, lacking in the others. The PK of the population was best described by a two-compartment population model. Mean (standard deviation, SD) population parameters included volume of distribution of central compartment: 0.45 (0.084) L/kg; total body clearance: 0.0476 (0.0147) L/h/kg; distribution rate constants, central to peripheral compartment (k(12)): 0.24 (0.12)/h, and peripheral to central (k(21)): 0.70 (0.22)/h. Mean maximal plasma concentration was 85 (19) mg/L. DISCUSSION: The addition of ivLEV to the standard regimen for controlling SE seems feasible and safe. PK data of ivLEV in patients with SE correspond to earlier values derived from healthy volunteers, confirming a two-compartment population model.
机译:目的:评估在患有癫痫持续状态(SE)的成人中,将静脉注射(iv)左乙拉西坦(LEV)加入标准治疗方案的可行性和安全性,并将其作为评估ivLEV人群药代动力学(PK)模型的次要目标SE。方法:在12名出现SE的成年人中,应根据需要尽快将2500 mg ivLEV添加到标准化方案中,该方案包括iv氯硝西am和/或直肠地西m,然后再加入苯妥英钠或丙戊酸。 ivLEV通常在氯硝西am给药后约5分钟内给药,无论是否需要进一步治疗。在24小时的随访期间,观察到患者有任何临床相关的副作用。有10名患者可获得用于PK分析的血液样本。通过迭代的两阶段贝叶斯分析建立了人口PK模型,并将其与健康志愿者的PK数据进行了比较。结果:每个方案分析中包括11名中位年龄为60岁的患者。五个被诊断为全身性惊厥SE,五个被诊断为部分性惊厥SE,一个被诊断为非惊厥SE。从入院到ivLEV的中位时间为36分钟。没有严重的副作用可能与ivLEV的给药直接相关。在PK分析期间,四名患者表现出明确的分布阶段,其他患者则缺乏。用两室人口模型最好地描述了人口的PK。平均(标准差,SD)总体参数包括中央隔室的分布体积:0.45(0.084)L / kg;全身清除率:0.0476(0.0147)L / h / kg;分布速率常数,中心到外围部分(k(12)):0.24(0.12)/ h,外围到中心(k(21)):0.70(0.22)/ h。平均最大血浆浓度为85(19)mg / L。讨论:在控制SE的标准方案中添加ivLEV似乎是可行和安全的。 SE患者中ivLEV的PK数据对应于健康志愿者的早期值,证实了两室人口模型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号